Table 1.
Subject characteristics (baseline)
| Patients with MS | |||||
| Healthy controls (n=27) |
All (n=151) |
Non-MSON (n=71) |
Unilateral MSON (n=50) |
Bilateral MSON (n=30) |
|
| Sex (N, female) | 12 (44) | 99 (66) | 45 (63) | 34 (68) | 20 (67) |
| Age (years) | 52.2±5.4 | 53.8±9.6 | 56.1±9.0 | 51.3±9.2 | 52.2±10.6 |
| Disease duration (years) | N/A | 20.8±6.5 | 20.3±6.5 | 20.4±6.5 | 22.9±6.1 |
| EDSS score | N/A | 3.5 (3.0–5.0) | 3.5 (3.0–6.0) | 3.5 (2.5–5.0) | 4.0 (3.0–4.5) |
| Disease course | |||||
| Relapsing–remitting (N) | N/A | 98 (65) | 42 (59) | 36 (72) | 20 (67) |
| Secondary progressive (N) | N/A | 34 (23) | 11 (32) | 14 (28) | 9 (30) |
| Primary progressive (N) | N/A | 19 (13) | 18 (25) | 0 (0) | 1 (3) |
| Current DMT use (N) | N/A | 44 (29) | 16 (23) | 19 (38) | 9 (30) |
| mGCIPL mean ODS (μm)* | 92.1±6.2 | 77.2±14.0 | 82.6±12.6 | 72.8±12.4 | 70.7±15.4 |
Data are shown as mean±SD, median (IQR) or N (%).
*Baseline GCIPL ODS values available for 24 healthy controls and 118 patients with MS.
DMT, disease modifying treatment; EDSS, Expanded Disability Status Scale; mGCIPL, macular ganglion cell and inner plexiform layer; MS, multiple sclerosis; MSON, multiple sclerosis-associated optic neuritis; N, number; N/A, not applicable; ODS, left and right eye.